While finding novel druggable targets and drug modalities for therapeutic intervention remains a top priority for the pharma/biotech industry, identifying and validating "good" targets and leads remains challenging. Cambridge Healthtech Institute’s conference on Proteomics-Driven Drug Discovery focuses on the use of mass spectrometry, biochemical, 
                                    
                                        
                                             
                                            26-27 September 2023